Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01661088 · ClinicalTrials.gov registry record · Phase 2
A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01661088 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 25 participants.
The verdict
NCT01661088, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The investigators hypothesize that the combination of the FOLFIRINOX regimen (a combination of 5-fluorouracil, irinotecan and oxaliplatin chemotherapy) to provide maximal systemic disease control and FDR-gemcitabine chemotherapy with concurrent IMRT (Radiation therapy) to address local disease, will achieve a significant improvement R0 resection (Radiation oncology repeat surgeries) rate in borderline resectable (surgical) pancreatic cancer and enhance disease free and overall survival in this patient population.
Interventions
- DRUG FOLFIRINOX
- RADIATION Intensity-modulated radiotherapy (IMRT)
- PROCEDURE Surgical Exploration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-06 |
| Est. Completion | 2019-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01661088
The ClinicalTrials.gov registry entry for NCT01661088 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which FOLFIRINOX is the first listed.
NCT01661088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01661088 about?
NCT01661088 is a clinical study titled "A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients". The investigators hypothesize that the combination of the FOLFIRINOX regimen (a combination of 5-fluorouracil, irinotecan and oxaliplatin chemotherapy) to provide maximal systemic disease control and FDR-gemcitabine chemotherapy with concurrent IMRT (Radiation therapy) to address local disease, will...
What is the current status of trial NCT01661088?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2011-06. Estimated completion is 2019-08-30.
What interventions are being tested in trial NCT01661088?
The interventions under investigation include: FOLFIRINOX (DRUG), Intensity-modulated radiotherapy (IMRT) (RADIATION), Surgical Exploration (PROCEDURE).
Who is sponsoring clinical trial NCT01661088?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.